Neochem Bio Solutions
Key Fundamentals
SMEChemicals & PetrochemicalsChemicalsPrice-based figures as of · TTM
- ROCE
- 28.10%
- Debt to Equity
- 0.23
- EPS (TTM)
- —
- Book Value
- ₹46.05
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 2.28
- ROE
- 25.40%
- Dividend Yield
- 0.00%
- EBITDA
- ₹15.10 Cr
- 52W High
- ₹121.00
- 52W Low
- ₹63.00
- Day Range
- ₹105.00 – ₹105.00
- Volume
- 1,200
Peer Comparison
Commodities › Chemicals › Specialty Chemicals
| ₹1,510.20 | 58.04 | ₹1,54,107 Cr | 13.72 | 1.42% | 23.90% | 31.00% | ₹15,399 Cr | ₹2,677 Cr | |
| ₹4,613.30 | 83.76 | ₹49,073 Cr | 6.04 | 0.07% | 7.82% | 9.64% | ₹5,303 Cr | ₹600 Cr | |
| ₹8,785.00 | 57.03 | ₹44,060 Cr | 10.10 | 0.09% | 19.60% | 21.00% | ₹3,634 Cr | ₹789 Cr | |
| ₹1,578.40 | 27.48 | ₹20,919 Cr | 3.32 | 0.49% | 9.82% | 11.40% | ₹8,575 Cr | ₹784 Cr | |
| ₹1,540.70 | 86.90 | ₹20,030 Cr | 7.88 | 0.00% | 9.66% | 11.90% | ₹1,231 Cr | ₹235 Cr | |
| ₹447.55 | 30.57 | ₹15,838 Cr | 2.59 | 0.23% | 7.13% | 6.86% | ₹9,010 Cr | ₹531 Cr | |
| ₹5,156.50 | 19.67 | ₹14,827 Cr | 2.31 | 0.59% | 11.50% | 14.90% | ₹6,969 Cr | ₹788 Cr | |
| Neochem Bio Solutions (this company) | ₹105.00 | — | ₹179 Cr | 2.28 | 0.00% | 25.40% | 28.10% | — | — |
| Median 8 companies | ₹1,559.55 | 57.03 | ₹20,474 Cr | 4.68 | 0.16% | 10.66% | 13.40% | ₹6,969 Cr | ₹784 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 81/100
Category scores
- Quality
- 67
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 31
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 76
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 69
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 87
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 39
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.8%
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 161 days.
- Working capital days have increased from 77.8 days to 164 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 4 | 7 | 8 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bullish | 2 | 0 | 8 |
Oscillators
Bearish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 50.78
- Neutral
- MACD (12,26,9)
- 0.56
- Bearish
- SMA (50)
- 102.98
- Bullish
- SMA (200)
- 89.98
- Bullish
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +32.24% |
|---|---|
| 1Y | +32.14% |
Net profit
| 3Y | +128.94% |
|---|---|
| 1Y | +71.43% |
Operating cash flow
| 3Y | Outflow widened by ₹16 Cr |
|---|---|
| 1Y | Turned negative |
Operating margin· change in pp
| 3Y | +9.69 pp |
|---|---|
| 1Y | +2.54 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2022 | ₹49.00 Cr |
|---|---|
| Mar 2023 | ₹48.00 Cr |
| Mar 2024 | ₹61.00 Cr |
| Mar 2025 | ₹84.00 Cr |
| Mar 2026 | ₹111 Cr |
Net profit by year
| Mar 2022 | ₹1.00 Cr |
|---|---|
| Mar 2023 | ₹1.00 Cr |
| Mar 2024 | ₹2.00 Cr |
| Mar 2025 | ₹7.00 Cr |
| Mar 2026 | ₹12.00 Cr |
Quarterly Results
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 47 | 65 |
| Expenses | 39 | 54 |
| Operating Profit | 8 | 11 |
| OPM % | 17% | 17% |
| Other Income | 2 | 1 |
| Interest | 2 | 2 |
| Depreciation | 1 | 1 |
| PBT | 7 | 10 |
| Tax % | 24% | 30% |
| Net Profit | 6 | 7 |
| EPS (₹) | 8.31 | 4.01 |
Profit & Loss
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 49 | 48 | 61 | 84 | 111 |
| Expenses | 45 | 44 | 55 | 71 | 91 |
| Operating Profit | 4 | 4 | 6 | 13 | 20 |
| OPM % | 7% | 9% | 10% | 15% | 18% |
| Other Income | 0 | 1 | 1 | 2 | 2 |
| Interest | 1 | 2 | 3 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 |
| PBT | 1 | 2 | 3 | 10 | 17 |
| Tax % | 25% | 28% | 31% | 25% | 30% |
| Net Profit | 1 | 1 | 2 | 7 | 12 |
| EPS (₹) | 3.23 | 2.1 | 2.89 | 11.15 | 7.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 7 | 7 | 17 |
| Reserves | 1 | 3 | 6 | 13 | 62 |
| Borrowings | 23 | 26 | 33 | 36 | 18 |
| Other Liabilities | 19 | 16 | 18 | 24 | 20 |
| Total Liabilities | 46 | 51 | 63 | 79 | 117 |
| Fixed Assets | 12 | 15 | 19 | 19 | 20 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| Other Assets | 34 | 36 | 45 | 60 | 91 |
| Total Assets | 46 | 51 | 63 | 79 | 117 |
Cash Flow
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | −1 | −1 | −1 | 2 | −17 |
| Investing | −3 | −3 | 12 | −1 | −9 |
| Financing | 4 | 4 | −11 | −1 | 26 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | −4 | −4 | 11 | 1 | −19 |
| CFO/OP | −36 | −23 | −10 | 23 | −70 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 102 | 107 | 100 | 110 | 161 |
| Inventory Days | 141 | 173 | 172 | 157 | 143 |
| Days Payable | 186 | 155 | 142 | 111 | 56 |
| Cash Conversion Cycle | 58 | 125 | 131 | 156 | 247 |
| Working Capital Days | 17 | 19 | 30 | 39 | 164 |
| ROCE % | — | 12% | 14% | 26% | 28% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Neochem Bio Solutions insights
55 extracted metrics across FY22–FY26.
Documents
- Concall · Sep 2026PPT
- Concall · Jul 2026PPT
- Concall · May 2026Transcript PPT
- Concall · Mar 2026PPT
- 28 Sep 2026
- 22 Sep 2026
- 21 Sep 2026
- 19 Sep 2026
Frequently Asked Questions about Neochem Bio Solutions
What does Neochem Bio Solutions Ltd do?
Where is Neochem Bio Solutions Ltd (NEOCHEM) listed?
Which sector does Neochem Bio Solutions Ltd belong to?
What is the 52-week high and low of Neochem Bio Solutions Ltd?
What is the Return on Equity (ROE) of Neochem Bio Solutions Ltd?
Company Information
Incorporated in 2006, Neochem Bio Solutions Ltd. is engaged in the business of manufacturing of specialty performance chemicals.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEOCHEM.md for Neochem Bio Solutions Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.